Risk factors for BK virus‐associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: A systematic review and meta‐analysis
Clinical Transplantation · 2023-11 · 37 (11)
DOI: 10.1111/ctr.15121 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Transplantation, online erschienen am 07.09.2023. Verfasst von Xuemei Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: BK Virus, Cystitis, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Basic Research Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective and Background BK virus‐associated hemorrhagic cystitis (BKV‐HC) is an intractable complication leading to higher mortality and prolonged hospitalization among allogeneic hematopoietic stem cell transplantation (allo‐HCT) recipients. Therefore, identifying the potential risk factors of BKV‐HC after allo‐HCT is crucial to improve prognosis and for early prevention. However, the risk factors for BKV‐HC remain debatable. Therefore, we conducted a systematic review and meta‐analysis to identify the risk factors for BKV‐HC, for early prevention of the occurrence of BKV‐HC and to improve the quality of life and prognosis of allo‐HCT recipients.
Methods
We searched relevant studies from PubMed, EMBASE, and the Cochrane Library up to February 2023. The odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) of all risk factors were calculated to evaluate their effects on the occurrence of BKV‐HC.
Results
Overall, 11 studies involving 2556 allo‐HCT recipients were included in this meta‐analysis. All included studies were retrospective and published between 2013 and 2022. We found that male sex (OR = 1.32; 95% CI, 1.07–1.62; p = .009, I 2 = 34%), haploidentical donor (OR = 1.84; 95% CI, 1.18–2.87; p = .007, I 2 = 23%), myeloablative conditioning (OR = 1.76; 95% CI, 1.36–2.28; p < .0001, I 2 = 45%), acute graft versus host disease (aGVHD) (OR = 2.73; 95% CI, 2.02–3.69; p < .0001, I 2 = 46%), chronic graft versus host disease (cGVHD) (OR = 1.71; 95% CI, 1.12–2.60; p = .01, I 2 = 0%), and cytomegalovirus (CMV) reactivation (OR = 3.13; 95% CI, 1.12–8.78; p = .03, I 2 = 79%) were significantly associated with BKV‐HC in the univariable analysis.
Conclusions
Our meta‐analysis indicated that male sex, haploidentical donor, myeloablative conditioning, aGVHD, cGVHD, and CMV reactivation were potential risk factors for BKV‐HC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China.
- Department of Quality and Safety Control, Zhongnan Hospital of Wuhan University, Wuhan, China.
Förderung
- National Basic Research Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhou, X., Zhang, S., Fan, J., Zhu, X., & Hu, S. (2023). Risk factors for BK virus‐associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: A systematic review and meta‐analysis. Clinical Transplantation, 37(11). https://doi.org/10.1111/ctr.15121
Vancouver
Zhou X, Zhang S, Fan J, Zhu X, Hu S. Risk factors for BK virus‐associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: A systematic review and meta‐analysis. Clinical Transplantation. 2023;37(11). doi:10.1111/ctr.15121
BibTeX
@article{Zhou2023,
author = {Zhou, Xuemei and Zhang, Senlin and Fan, Junjie and Zhu, Xiaoping and Hu, Shaoyan},
title = {Risk factors for BK virus‐associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: A systematic review and meta‐analysis},
journal = {Clinical Transplantation},
year = {2023},
volume = {37},
number = {11},
doi = {10.1111/ctr.15121}
}
EUVIMED